Evidence map›Paper›PMID 40006061›Full record

ArticlePharmaceuticals (Basel, Switzerland)2025

Amany Mohammed Mohmmed Hegab, Soha Osama Hassanin, Reham Hassan Mekky, Samah Sulaiman Abuzahrah, Alaaeldin Ahmed Hamza, Iman M Talaat, Amr Amin

Abstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Mechanistic pathways andIranian journal of basic medical sciences · 2026
    Article
  13. Article
  14. Oroxylin A FromCanadian respiratory journal · 2026
    Article
  15. Article
  16. Article
  17. Article
  18. Study the impact ofCytotechnology · 2025
    Article
  19. International journal of molecular sciences · 2025
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Amany Mohammed Mohmmed HegabDevelopmental Pharmacology and Acute Toxicity Department, Egyptian Drug Authority (EDA), Formerly National Organization of Drug Control and Research (NODCAR), Giza 12611, Egypt.
Soha Osama HassaninBiochemistry Department, Faculty of Pharmacy, Modern University for Technology and Information, Cairo 11585, Egypt.ORCID 0000-0001-8568-1033
Reham Hassan MekkyDepartment of Pharmacognosy, Faculty of Pharmacy, Egyptian Russian University, Badr City, Cairo-Suez Road, Cairo 11829, Egypt.ORCID 0000-0001-5613-5666
Samah Sulaiman AbuzahrahSamah Sulaiman Abuzahrah, Department of Biological Sciences, College of Science, University of Jeddah, Jeddah 21959, Saudi Arabia.
Alaaeldin Ahmed HamzaBiology Department, Egyptian Drug Authority (EDA), Formerly National Organization of Drug Control and Research (NODCAR), Giza 12611, Egypt.ORCID 0000-0001-5450-1116
Iman M TalaatClinical Sciences Department, College of Medicine, University of Sharjah, Sharjah 27272, United Arab Emirates.ORCID 0000-0002-5259-327X
Amr AminResearch Institute for Medical and Health Sciences, University of Sharjah, Sharjah 27272, United Arab Emirates.ORCID 0000-0001-8888-1102

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

anti-inflammatorydoxorubicinnephrotoxicityoxidative stresstherapeutic efficacyWithania somnifera

Identifiers

PMID40006061
PMCPMC11859695

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.